Genetic Diversity of Mycobacteriophages and the Unique Abilities of Cluster K by Morris, Shea A
The Corinthian 
Volume 18 Article 5 
June 2017 
Genetic Diversity of Mycobacteriophages and the Unique Abilities 
of Cluster K 
Shea A. Morris 
Georgia College and State University 
Follow this and additional works at: https://kb.gcsu.edu/thecorinthian 
 Part of the Virology Commons 
Recommended Citation 
Morris, Shea A. (2017) "Genetic Diversity of Mycobacteriophages and the Unique Abilities of Cluster K," 
The Corinthian: Vol. 18 , Article 5. 
Available at: https://kb.gcsu.edu/thecorinthian/vol18/iss1/5 
This Article is brought to you for free and open access by the Undergraduate Research at Knowledge Box. It has 
been accepted for inclusion in The Corinthian by an authorized editor of Knowledge Box. 
 
Introduction: 
Mycobacteriophages make up a large portion of particles in the biosphere reaching 
1030  in number (Hatfull et al., 2006). These phages are viruses that also infect large, 
diverse amounts of bacteria, destroying the bacteria that they infect. 
Mycobacteriophage are so numerous that it is estimated 1023 phage infections of 
their bacterial host occur every second. Their genetics are extremely diverse, 
although, each individual mycobacteriophage has a specific bacterial host range 
that is typically restricted to a single genus of bacterium. On rare occasions; 
however, some phage have a host range outside one genus of bacteria (Pope et al., 
2011a). Due to mycobacteriophages large host range, each phage has a specific 
viral life cycle which allows them go through lytic, lysogenic cycles, or sometimes 
a combination of the two. This diversity in pathogenic mechanisms allows 
mycobacteriophage to have a powerful effect on each bacterium it is introduced to 
and that is why the group is attractive for viral- based antibiotic agents to assist or 
replace conventional antibiotics. Conventionally, these viral approaches to bacterial 
control are often referred to as “phage therapy” in medical practice. 
Mycobacteriophages are arranged in clusters and subclusters based on 
similar genetics, and the cluster K is of particular interest as it is rather small 
compared to other clusters, but also incredibly unique. The phages within the 
cluster K are temperate phages and many believe have the ability to aid in research 
on tuberculosis genetics and act as a bactericidal to fight mycobacterial infections 
(Pope et al., 2011b). Through past and present therapies these phage may be used 
as an oral cocktail for patients to drink or as an injection that induces sensitivity to 
antibiotics in the bacterial cell, allowing for it to be killed by either antibiotics or 
the phage. Through this treatment, less antibiotic resistance would develop and any 
genetic changes made by bacteria to resist mycobacteriophage would induce a 
similar genetic mutation in the phage group to maintain its viral abilities against 
mycobacteria (Flatow & Spellberg, n.d.). In this paper it will be these qualities that 
are discussed to emphasize the importance of mycobacteriophage and what makes 
them genetically unique and useful in medical practice.  
The Virus: 
Mycobacteriophage are bacterial viruses (bacteriophages) that are compromised of 
nucleic acid surrounded by a protein capsid (Pierce, 2005). Their chromosomes are 
composed of double stranded DNA and show much morphological and genetic 
diversity. The vast entity that bacteriophages represent in the biosphere has allowed 
for around 8,000 bacteriophages to be found (The Actinobacteriophage Database, 
n.d.). Therein, these phages are divided into clusters and subclusters based on their 
genetic similarities and host range. However, even phage within the same cluster 
or subcluster can be extremely diverse. Broad genomic studies are necessary to 
improve what science knows about mycobacteriophage because there are too many 
for all to be studied specifically. While only a few phage have been studied 
 
specifically, enough study of their genetic data leads researchers to believe that 
phage within the same cluster and subcluster can effectively infect the same 
mycobacteria. If this assumption is consistent with all mycobacteriophage then 
there may well be a large variety of phage to combat most any mycobacterial 
disease. 
Mycobacteriophage Morphologies: 
Based on characteristics noted to date, all mycobacteriophages are classified as 
either siphoviral or myoviral. The more common, siphoviral phage have long, 
flexible tails that do not contract, while myoviral phage have shorter contractile 
tails. Their tail length can be from 135 nm to 350 nm and usually clusters show 
similar tail length. Each capsid head size is based on the genome length of the phage 
(Hatfull, 2014b). All mycobacteriophage have an isometric icosahedral capsid 
head, although for some, the viral head is more prolated. Additionally, all phage 
that have double stranded DNA and tails are referred to as Claudovirales (Pope et 
al., 2011a). In Cluster K, most members are siphoviral and their tails range from 
185 nm to 200 nm (Hughes & Wolyniak, 2014). Sometimes Cluster K phage have 
tail fibers at the end of their tails and their capsid heads are usually around 50 to 60 
nm in diameter (Pope et al., 2011b). These characteristics have been determined by 
transmission electron microscopy, typically with a negative stain such as uranyl 
acetate. Mycobacteriophages that have been examined show fewer morphological 
differences compared to other types of viruses. Whether that is because differences 
do not exist, or have yet to be found, is unknown. Nevertheless, many researchers 
believe this restricted phage morphology has been under positive selection 
throughout their evolution. 
Host Range: 
All mycobacteriophage have a specific host range, typically for only one genus of 
mycobacterium. The most common mycobacterium used to isolate 
mycobacteriophage is M. smegmatis. Almost all known mycobacteriophage were 
isolated on M. smegmatis lawns; however, many other bacteria are also used as 
hosts, such as, Pseudomonas, Salmonella, Staphylococcus, and many others (Pope 
et al., 2011a). Because of this, the full host range of some phages have yet to be 
fully examined; therefore, it is possible that many other mycobacteria may be 
potential hosts that have yet to be experimented with (Sarkis & Hatfull, 1998). 
Phage are isolated on bacteria by either direct plating or enrichment. While 
enrichment produces the most amount of phage, some research indicates that it may 
lower the genetic diversity of the phage by continuing to grow it through 
enrichment (Pope et al., 2011a). The gene that most determines host range has yet 
to be found, but many viral researchers have come to believe that it resides on the 
phage’s tail proteins (Sarkis & Hatfull, 1998). The further scientists study the host 
range of phages, the more information they will have to explain some of the 
evolutionary patterns of phage development as well as many other aspects (Hatfull 
 
et al., 2010). Through genome analysis, many mycobacteriophage share similar 
nucleotide sequences in comparison to the mycobacterium they infect which is why 
the study of bacteriophages offers extensive insight on bacterial genetics and life 
cycles (Hatfull et al., 2010).  
One of the most exciting aspects of phage biology is the fact that many 
mycobacteriophage infect M. avium and M. tuberculosis. These two hosts have 
received a lot of study in recent years due to their resistance to antibiotics and their 
roles in pathogenesis. Mycobacteriophage have the potential to solve this problem 
as some mycobacteriophage can infect and kill both bacteria (Broxmeyer et al., 
2002). The greatest issue in phage research is the development of a vehicle that can 
transport phage DNA safely into a plasmid and into the bacteria cell of the host. 
These vehicles are being created today and are called phasmids (Bardarov et al., 
1997). 
 The integration of phage DNA into a bacteria cell can alter the physiology 
of the bacteria cell by adding viral genes and altering bacterial genes (Hatfull, 
2014a). Phages either enter a host in a lytic or lysogenic cycle and those that enter 
a lysogenic phase may shift to a lytic cycle if the bacterial environment is no longer 
favorable in maintaining the prophage. The lytic virus enters the cell and begins to 
replicate itself within the host destroying the bacteria’s DNA. The virus takes over 
the cell and once the virus has encoded enough new parts it lyses the cell and 
releases the new phages. In a lysogenic viral cycle, the virus remains dormant and 
a part of the hosts DNA, this is known as a prophage. Virulent phages only exhibit 
the lytic cycle and are very dangerous for the bacteria in which they infect. Some 
mycobacteriophage, such as Cluster K, are temperate phages. These phages can 
enter and exit from lytic and lysogenic cycles whenever it fits their needs (Sarkis 
& Hatfull, 1998). Cluster K also exhibit a host range between both slow and fast 
growing bacteria including M. tuberculosis, M. avium, M. uclerans and M. 
smegmatis. The plaque formation on M. tuberculosis is different for each Cluster K 
phage; however, they infect and kill the bacterium effectively (Pope et al., 2011b). 
Grouping: 
Phage are grouped using a simple dotplot nucleic acid hybridization analysis that 
compares genomes. Many dotplots have been performed over various groups of 
mycobacteriophage and they all show significant diversity throughout the entire 
phage population. In order to easily identify phage, clusters and subclusters have 
been formed to show the genomic similarities of certain phage. In order for a phage 
to be part of a cluster it must share up to 50% of the same nucleotide sequence of 
at least one other phage within the cluster. If a phage does not show significant 
similarities in its nucleotide sequence to any group of phage it will be placed into a 
separate new cluster; these phages are known as singletons and only five are known 
at this time (Hatfull, 2014b). Along with using dot plots to analyze phage, 
researchers also use a program called Phamerator which divides the phages into 
 
‘phamilies’ by sorting their amino acid sequence similarities (The 
Actinobacteriophage Database, n.d.). Through this program and others, it can be 
demonstrated that mycobacteriophage have gone through extensive horizontal gene 
transfer during their evolution, as this gene transfer is not only within a phage 
cluster, but generally exhibited over the entire mycobacteriophage population. 
Based on this knowledge it is thought that most phage come from a common, but 
constantly evolving, gene pool (Pedulla et al., 2003).  
Cluster K phage show extensive similarities among subcluster K1 phages, 
particularly toward the left side of their genome, and there is a more distant 
relationship between the nucleotide sequences between K1 and, K2 and K3. Their 
genome architecture is similar with each subcluster sharing many similar genes 
(Pope et al., 2011b). Recently researchers are working towards developing a new 
method of phage classification that only involves analyzing the “tapemeasure” gene 
of phage. This gene is the longest and through this method it would be much easier 
to place phages into specific clusters (Smith et al., 2013). In all there are a total of 
19 clusters from A to S and a few of these are then divided into subclusters. While 
the use of clusters makes searching for phage with a specific genome easier, it does 
not explain the full evolutionary history of these phage as evolutionary patterns 
determined by cluster analysis cannot entirely reveal the pattern by which they 
evolved (Hatfull, 2014b). 
Genome: 
Gene analysis of mycobacteriophage further shows the diversity and mosaicism of 
mycobacteriophage. The genomes vary in length from 25 to 200 kilobase pairs and 
the use of illegitimate recombination leads to huge amounts of diversity in the 
phage population (Hatfull et al., 2006). Each segment of phage genome has a 
unique evolutionary history; some phage lack certain segments compared to their 
relatives which can indicate the order of when specific phage evolution began. Even 
so, mapping of this evolutionary history is extremely difficult; however, as the 
research moves forward, a better understanding of these patterns will be discovered 
that explain the uniqueness of each phage.  
 Mycobacteriophage genomes tend to have a precise order for their virion 
and assembly genes; typical they are on the left side of the genome and can be easily 
identified (Hatfull et al., 2010). The genes are tightly packed and have little 
noncoding space, roughly ranging from 400 to 800 base pairs (Hatfull et al., 2010). 
While it is likely that nearly all the viral genes have been predicted, many are genes 
that as yet have no known function (Hatfull, 2014b). The average amount of protein 
coding genes per genome is 114 and the protein domains are commonly small, 
containing less than 60 residues (Hatfull et al., 2010). Some phage encoding 
proteins could serve as antibacterial products in medical therapies (Drulis-Kawa, 
Majkowska-Skrobek, Maciejewska, Delattre & Lavigne, 2012). Mycobacteriphage 
have proteins that encode for lytic or lysogenic cycles, and therefore is a key gene 
 
determinate for whether a phage is virulent and of use in therapeutic practice. A 
few mycobacteriophage have a protein that catalyzes recombination; however, this 
gene cannot be found on all mycobacteriophage, leading researchers to believe 
there are many variations of enzymes that catalyze recombination in 
mycobacteriophage (Hatfull et al., 2010). Similarly, certain phage have DNA 
polymerase to help synthesize their DNA and others do not. The appearance and 
loss of genes definitely play a significant role in the history of phage, and in some 
cases, they may indicate one phage being a parent of another. Due to complexities 
or missing information, they may, in other, cases exist in too many variations of a 
particular gene to be discoverable (Hatfull et al., 2010). Most phage have a 
reasonable amount of tRNA genes and a few even have tmRNA genes (Hatfull et 
al., 2006). tmRNA helps terminate translation of mRNA that becomes blocked due 
to the lack of a stop codon in the transcript, a common occurrence when the mRNA 
is degraded from its 3’ end. Thus, the encoding of tRNA and tmRNAs by the phage 
ensures it will have sufficient translational machinery to express proteins needed to 
complete its lifecycle. These are just a few differences in the phage genomes, and 
demonstrate why these phage are so genetically diverse. 
 The most obvious genomic difference in Cluster K phages is the size of the 
genome of the phage TM4, compared to all other phages within the cluster. TM4 is 
smaller than all the other phage in Cluster K and it is also the only phage within the 
cluster that is not temperate. It lacks a section of the genome which codes for 
different parts of the lytic and lysogenic cycles in other Cluster K phages, leading 
researchers to believe it has gone through a deletion from its original parent’s 
genome. Cluster K is like most mycobacteriophage in that their virion and assembly 
genes lie to the left and they have a section of genes with no known function (Pope 
et al., 2011b).  
Phage Therapy: 
Phage therapy is not a new topic, it has been discussed and practiced for decades 
since the first mycobacteriophage was plated on M. tuberculosis. However, with 
the adoption of widespread use of traditional antibiotics therapies (e.g., penicillin) 
in the western world, phage therapy has had little new experimentation and 
discussion since the 1930s, and it has remained this way until the past two decades. 
The focus of phage therapy is introducing phage as the new way to kill bacteria 
instead of antibiotics. Due to the extensive use of antibiotics, antibiotic resistance, 
and lack of new discoveries in the field of antibiotic development, effective new 
antibiotic treatments are waning. Indeed, the population most affected by this 
detrimental dilemma are patients suffering from chronic bacterial infections. In 
1993 the World Health Organization declared multi-drug resistant tuberculosis 
(MDRTB) as a global emergency due to its high risk of fatalities and its antibiotic 
resistance (Bardarov et al., 1997). Since this time researchers have begun to 
intensely study the use of phage in tuberculosis therapy as Cluster K, as well as 
 
other phage clusters, can infect and kill M. tuberculosis. The most difficult process 
has been creating a transport vehicle that would allow mycobacteriophage to enter 
the human body; however, many therapies are being developed and used to over 
come this.  
The Beginnings of Phage Therapy:  
Phage therapy was first practiced in Europe over one hundred years ago and has 
since been continued to be studied in that area. In France, around 1919, Dr. 
d’Herrelle began experimenting in intravenous injection of phage to children with 
dysentery; however, many of his first clinical trials were not printed until he felt 
that he had done enough research on phage to write a set of books explaining his 
clinical applications and extensive study of phage (Alavidze & Kutateladze, 2001). 
Russia has used phage therapy since the 1930s when Georgia began a facility 
specifically for producing phage and sending them to Russian war camps. Indeed, 
Russian soldiers in this period were known to carrier canisters of phage which were 
used to treat diarrhea and wounds. Russia and Georgia both performed phage 
therapy throughout the past 90 years and continue to produce new phage cocktails 
for the open market. In the western world, the study of phage began to dissipate 
when the use of traditional antibiotics began in the medical field. Since traditional 
antibiotics, prior to the development of antibiotic resistance, worked tremendously 
well as an effective treatment for bacterial infections, most phage research was set 
aside (Abedon, Kuhl, Blasdel & Kutter 2011). With the advent of growing 
antibiotic resistance, research on phage therapy has ramped up in the last twenty 
years. Clinical trials are now being performed by multiple United States universities 
and through continued trials it is expected that phage cocktails may reach the 
pharmaceutical market in potentially less than five years (Flatow, Spellberg & 
Turner, n.d.).  
Therapy Types: 
The beauty of phage therapy is the ability for it to be used in many ways. 
Intravenous therapy was one of the first experimented therapies. In this practice, 
small amounts of phage were isolated and mixed into a saline solution which was 
then infused into the blood over a bacterial infection. Patients experienced a 
decrease in the bacterial infection after 48 hours; however, the trial notes indicate 
that some patients may have experienced violent reactions at the beginning of their 
infusion (Abedon, Kuhl, Blasdel & Kutter 2011. Since these early experiments, 
little intravenous phage therapy has been published. Researchers, working in the 
Eastern European country of Georgia, have developed two phage cocktails that are 
used in a myriad of ways. “Intestiphage” and “Pyophage” are the two phage 
cocktails on the open market in Georgia. “Intestiphage” can be ingested orally and 
fights against 20 different types of gut bacteria and is often distributed in war zones. 
Other therapies with “Pyophage” have been created to make “PhagoBioDerm,” a 
bandage or wrap with the “Pyophage” cocktail inside that allows for the phage to 
 
slowly infuse over a wound over days or be placed directly inside the wound 
(Abedon, Kuhl, Blasdel & Kutter 2011). 
In the United States, clinical trials are being performed on another version 
of phage therapy (Chan et al. 2016). These trials involve injecting phage cocktails 
into the area of bacterial infection, this allows for the phage to attack the bacterial 
cell and the cell may either protect itself from the virus or maintain its defense 
systems against traditional antibiotics; however, it cannot do both. Therefore, either 
the bacterial cell is destroyed by the phage or traditional antibiotics are used while 
the bacterial cells defenses are decimated as it protects itself against the phage. This 
genetic trade off with the bacteria either evolving to increase the resistance against 
phage or become sensitive to antibiotics has the potential to become a viable 
bacterial infection treatment throughout the United States (Chan et al. 2016). This 
combined antibiotic-phage therapy allows for any potential bacteria that are not 
harmful to be saved while the infectious bacteria are killed. Currently, antibiotics 
can kill both useful and detrimental bacteria, sometimes leading to more issues for 
the patients once the natural flora of bacteria are killed (Bacteriophage Therapy, 
2015). 
Cluster K’s role in fighting Tuberculosis:  
Cluster K phages infect M. tuberculosis, making them prime candidates for the 
studies discussed above. They are temperate phages which allows them to enter 
both lytic and lysogenic cycles while in the bacteria cell (Pope et al., 2011b). 
Potentially they could be inserted into the body to fight the M. tuberculosis bacteria 
that is in the body at that time and then remain in a lysogenic form until more M. 
tuberculosis is found. An oral cocktail could also be developed using these 
mycobacteriophage. The other potential therapy would be the injection of phage 
into the infected area and causing the bacteria to evolve and protect itself from the 
phage while the antibiotics go in and kill the cell. At the moment, only phage TM4 
in Cluster K has had extensive research performed on it; however, hopefully in the 
future more Cluster K phages can be used and put into practice with these therapies.  
Our Lab’s Role in Cluster K Phage Discovery 
At this time, two novel Cluster K phages have been isolated in our lab, in the 
Department of Biological & Environmental Sciences at Georgia College. Phage 
Milly belongs to subcluster K2 and has been sequenced and the genome has been 
annotated. The other phage is Adonis, which is part of subcluster K1 and has 
recently been isolated and sequenced. Future plans for the lab include the genome 
annotation of the most Cluster K phage Adonis, as well as lysogeny tests both 




Figure 1: Electron microscopy pictures of Milly (left) and Adonis (right) 
Conclusion: 
Mycobacteriophages are extremely diverse in their genetics with many diverging 
evolutionary path ways. They infect many types of mycobacteria and remain 
extremely specific to their host range. Each phage goes through lytic and/or 
lysogenic cycles allowing them to destroy the bacteria they infect. Due to their 
broad host range and genetic differences each phage cluster has the potential to 
push through antibiotic resistance barriers and transform the world of antibiotics. 
Specifically, Cluster K phages can infect M. tuberculosis, and could serve as a tool 
to eradicate the growing disease of MDRTB. As research moves forward new and 
old therapies will be expanded and the use of mycobacteriophage, such as Cluster 
K, will likely become more common.  
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